Miguel Forte

Miguel Forte is CEO of Bone Therapeutics, a Professor at Lisbon University and Board of Directors an Executive Committee member for ARM and a Board Member for Essenscia-Wallonie.

Miguel Forte assumed his role as President-Elect of ISCT in May 2022. Previously, he was Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020) leading the expansion of the industrial community, strengthening the Committee to better represent the industrial translational objectives and needs of society membership.

Previously, as CEO of Zelluna Immunotherapy (2017-2019), he established the corporate structure, built the team and launched the strategy for solid tumours allogeneic C&GT. From 2010-2017 Miguel was CMO/COO of TxCell, establishing and leading the professional C&GT product translation development for autoimmune diseases and also participating in the company IPO and several successful raises.

Holds an M.D. and Specialist in Infectious Diseases from the Faculty of Medicine, University of Lisbon, a PhD in Immunology, University of Birmingham, and a certificate in Health Technologies Economics, Stockholm School of Economics. He is a Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.